Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia.

Abstract

BACKGROUND:

Storage symptoms, associated with benign prostatic hyperplasia (BPH), often co-exist with voiding symptoms in men with lower urinary tract symptoms (LUTS). Storage symptoms are likely to be most bothersome, and may not be adequately resolved by treatment with α-blocker or antimuscarinic monotherapy. A recent randomised controlled phase 3 trial (NEPTUNE) demonstrated that a fixed-dose combination (FDC) of solifenacin 6 mg plus an oral controlled absorption system (OCAS™) formulation of tamsulosin (TOCAS, 0.4 mg) improved storage symptoms, as well as quality of life, compared with TOCAS alone in men with moderate-to-severe storage symptoms and voiding symptoms. This analysis aimed to assess the cost-effectiveness of a FDC tablet of solifenacin 6 mg plus TOCAS relative to tolterodine plus tamsulosin given concomitantly, from the perspective of the UK National Health Service (NHS).

METHODS:

A Markov model was developed for men aged ≥45 years with LUTS/BPH who have moderate-to-severe storage symptoms and voiding symptoms. The model calculated cost-effectiveness over an analytical time horizon of 1 year and estimated total treatment costs, quality adjusted life years (QALYs) and incremental cost-effectiveness ratio.

RESULTS:

The FDC tablet of solifenacin 6 mg plus TOCAS was associated with lower total annual costs (£860 versus £959) and increased QALYs (0.839 versus 0.836), and was therefore dominant compared with tolterodine plus tamsulosin. Time horizon, discontinuation or withdrawal rates, drug cost and utility values were the main drivers of cost-effectiveness. The probability that the FDC tablet of solifenacin 6 mg plus TOCAS is cost-effective was 100% versus tolterodine plus tamsulosin, at a willingness-to-pay threshold of £20,000/QALY gained.

CONCLUSIONS:

The FDC tablet of solifenacin 6 mg plus TOCAS provides important clinical benefits and is a cost-effective treatment strategy in the UK NHS compared with tolterodine plus tamsulosin for men with both storage and voiding LUTS/BPH.

• Authors: Jameel Nazir, Lars Heemstra, Anke van Engen, Zalmai Hakimi, Cristina Ivanescu
• Journal: BMC urology (BMC Urol) Vol. 15 Pg. 41 (May 09 2015) ISSN: 1471-2490 [Electronic] England
• PMID: 25956727 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Delayed-Action Preparations
• Drug Combinations
• Sulfonamides
• Tolterodine Tartrate
• Tamsulosin
• Solifenacin Succinate

Topics

• Administration, Oral
• Aged
• Aged, 80 and over
• Cost-Benefit Analysis
• Delayed-Action Preparations (economics, pharmacokinetics)
• Drug Combinations
• Drug Therapy, Combination
• Follow-Up Studies
• Humans
• Lower Urinary Tract Symptoms (drug therapy, etiology, physiopathology)
• Male
• Markov Chains
• Middle Aged
• Prostatic Hyperplasia (complications, diagnosis)
• Severity of Illness Index
• Solifenacin Succinate (administration & dosage, economics)
• Sulfonamides (administration & dosage, economics)
• Tamsulosin
• Tolterodine Tartrate (administration & dosage, economics)
• Treatment Outcome
• Urodynamics